ChiCTR2300071080 版本V1.0 版本创建时间2023/05/04 14:42:36 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300071080 

最近更新日期:

Date of Last Refreshed on:

2023-05-04 14:42:16 

注册时间:

Date of Registration:

2023-05-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

微创肺切除术对同侧肺部残余结节的影响: 一项多中心双向队列研究

Public title:

Effect of minimally invasive pulmonary resection on residual nodules in the ipsilateral lung: a multicenter bidirectional cohort study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

微创肺切除术对同侧肺部残余结节的影响: 一项多中心双向队列研究

Scientific title:

Effect of minimally invasive pulmonary resection on residual nodules in the ipsilateral lung: a multicenter bidirectional cohort study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王春平 

研究负责人:

王春平 

Applicant:

Chunping Wang 

Study leader:

Chunping Wang 

申请注册联系人电话:

Applicant telephone:

+86 13917965435

研究负责人电话:

Study leader's
telephone:

+86 13917965435

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

flybee2022@126.com

研究负责人电子邮件:

Study leader's E-mail:

flybee2022@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市普陀区新村路389号

研究负责人通讯地址:

上海市普陀区新村路389号

Applicant address:

389 Xincun Road, Putuo District, Shanghai

Study leader's address:

389 Xincun Road, Putuo District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市同济医院(同济大学附属同济医院)

Applicant's institution:

Shanghai Tongji Hospital (Tongji Hospital of Tongji University)

研究负责人所在单位:

上海市同济医院(同济大学附属同济医院)

Affiliation of the Leader:

Shanghai Tongji Hospital (Tongji Hospital of Tongji University)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(同)伦审第(2023-017)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市同济医院(同济大学附属同济医院)伦理委员会

Name of the ethic committee:

Shanghai Tongji Hospital (Tongji Hospital of Tongji University) Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2023-01-18 00:00:00

伦理委员会联系人:

宣淼

Contact Name of the ethic committee:

Miao Xuan

伦理委员会联系地址:

上海市普陀区新村路389号

Contact Address of the ethic committee:

389 Xincun Road, Putuo District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 66111243

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市同济医院(同济大学附属同济医院)

Primary sponsor:

Shanghai Tongji Hospital (Tongji Hospital of Tongji University)

研究实施负责(组长)单位地址:

上海市新村路389号

Primary sponsor's address:

389 Xincun Road, Putuo District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

CHINA

Province:

Shanghai

City:

单位(医院):

上海市同济医院(同济大学附属同济医院)

具体地址:

上海市新村路389号

Institution
hospital:

Shanghai Tongji Hospital (Tongji Hospital of Tongji University)

Address:

389 Xincun Road, Putuo District, Shanghai

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

CHINA

Province:

Shanghai

City:

单位(医院):

上海市胸科医院

具体地址:

上海市淮海西路241号

Institution
hospital:

Shanghai Chest Hospital

Address:

241 Huaihai West Road, Shanghai

经费或物资来源:

上海市同济医院青年培育项目

Source(s) of funding:

Shanghai Tongji Hospital Youth cultivation project

研究疾病:

肺部疾病  

Target disease:

Pulmonary disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

通过将患者残余肺结节分为两组,手术侧残余肺结节组和手术对侧残余肺结节组,以手术对侧残余结节作为对照组,以残余肺结节的生长为主要观察指标,对比两侧残余肺结节术后生长趋势的差异,探究微创肺部结节切除手术对于手术侧残余结节生长的影响及残余肺结节生长的危险因素,优化多发肺结节治疗方案,减少可能再次手术、或其他治疗的风险,并最大程度保留肺组织和肺功能,更好的管理残余肺结节,为残余肺结节精准管理提供依据。  

Objectives of Study:

The patients' residual pulmonary nodules were divided into two groups, the surgical residual pulmonary nodules group and the contralateral residual pulmonary nodules group. The contralateral residual pulmonary nodules were taken as the control group, and the growth of residual pulmonary nodules was taken as the main observation index to compare the differences in the postoperative growth trend of residual pulmonary nodules on both sides. To explore the effects of minimally invasive pulmonary nodule resection on the growth of residual pulmonary nodules at the surgical side and the risk factors for the growth of residual pulmonary nodules, optimize the treatment of multiple pulmonary nodules, reduce the risk of repeated surgery or other treatments, preserve lung tissue and lung function to the maximum extent, and better manage residual pulmonary nodules, so as to provide the basis for accurate management of residual pulmonary nodules.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1) 术前胸部CT检查提示为多发GGO,GGO数目大于两个; (2) 根治性切除主病灶; (3) 术前至少2次胸部CT检查提示GGO无吸收情况; (4) 术后病理学检查诊断为不典型腺瘤样增生(atypical adenomatous hyperplasia,AAH)、原位腺癌(adenocarcinoma in situ,AIS)、微浸润腺癌 (microinvasive lung adenocarcinoma。MIA)、浸润性腺癌(invasiveadenocarcinoma,IA)的患者; (5) 术后规范随访,术后两年内每3-6随访一次,术后两年每6-12月随访一次,每半年有CT检查报告; (6) 术后有残余结节; (7) 术前无化疗史; (8) 无其他部位肿瘤史;

Inclusion criteria

1) Preoperative chest CT examination indicated multiple Ggos, with more than two Ggos; (2) Radical resection of the main focus; (3) At least two preoperative chest CT examinations indicated no GGO absorption; (4) Postoperative pathological examination was atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ, the atypical atypical adenomatous hyperplasia, adenocarcinoma in situ, AIS), microinvasive lung adenocarcinoma. MIA), invasiveadenocarcinoma (IA); (5) Standardized follow-up was conducted every 3-6 years in the two years after surgery, and every 6-12 months in the two years after surgery. CT examination report was available every six months. (6) Residual nodules after operation; (7) No history of chemotherapy before (8) No history of tumors in other sites;

排除标准:

(1) 术后30天死亡; (2) 术后残余结节缩小或消失; (3) 术后无规范随访; (4) 术后无清晰的胸部CT片;

Exclusion criteria:

(1) death 30 days after surgery; (2) Residual nodules reduced or disappeared after surgery; (3) No standardized follow-up after surgery; (4) Postoperative chest CT images were not clear;

研究实施时间:

Study execute time:

From 2023-01-01 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-05-02 00:00:00 To 2023-12-31 00:00:00

干预措施:

Interventions:

组别:

肺切除手术同侧残余结节组

样本量:

380

Group:

Group with residual nodules ipsilateral to lung resection surgery

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

组别:

肺切除手术对侧残余结节组

样本量:

380

Group:

Group with residual nodules on the contralateral side of lung resection surgery

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市同济医院(同济大学附属同济医院) 

单位级别:

三甲 

Institution
hospital:

Shanghai Tongji Hospital (Tongji Hospital of Tongji University)

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学医学院附属胸科医院 

单位级别:

三甲 

Institution
hospital:

Chest Hospital affiliated with Shanghai Jiao Tong University School of Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

残余肺结节直径

指标类型:

主要指标

Outcome:

Residual lung class diameter

Type:

Primary indicator

测量时间点:

术后每半年

测量方法:

CT检查

Measure time point of outcome:

Postoperatively every six months

Measure method:

CT examination

指标中文名:

新发结节

指标类型:

次要指标

Outcome:

New nodule

Type:

Secondary indicator

测量时间点:

术后每半年

测量方法:

CT检查

Measure time point of outcome:

Postoperatively every six months

Measure method:

CT examination

指标中文名:

患者肺功能的改变

指标类型:

次要指标

Outcome:

Changes in patients' pulmonary function

Type:

Secondary indicator

测量时间点:

术后每半年

测量方法:

Measure time point of outcome:

Postoperatively every six months

Measure method:

指标中文名:

局部复发

指标类型:

次要指标

Outcome:

Local recurrence

Type:

Secondary indicator

测量时间点:

术后每半年

测量方法:

Measure time point of outcome:

Postoperatively every six months

Measure method:

指标中文名:

远处转移

指标类型:

次要指标

Outcome:

Distant metastasis

Type:

Secondary indicator

测量时间点:

术后每半年

测量方法:

Measure time point of outcome:

Postoperatively every six months

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

NO

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

no

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

no

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

no

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-05-04 14:42:16